SHAPIRO MEDICAL, LLC
JACKSONVILLE, FLORIDA

Shapiro Medical LLC, formally known as the Shapiro Medical Group, is a leader in hair transplantation under the skilled guidance of renowned physician Dr. Ron Shapiro MD. Recognized worldwide for his contributions to Follicular Unit Hair Transplantation, Dr. Shapiro co-authored the seminal medical textbook 'Hair Transplantation,' often referred to as the "Bible" within the field. His expertise has significantly influenced advancements in hair restoration techniques globally. The practice also includes Dr. David Josephitis, a prominent hair transplant surgeon who joined the group in 2013. Graduating with training from respected physicians in the industry, Dr. Josephitis is affiliated with major boards such as ABHRS and ISHRS. His commitment extends beyond surgical procedures to include aesthetic enhancements through injectables like Juvederm® and Botox. Operational excellence at Shapiro Medical Group is supported by a team of professionals dedicated to patient care and education. Andrew Russell, the Business Operations Manager with over 12 years at the firm, leads in managing administrative functions, while Kelly facilitates patient interaction from initial assessments through postoperative care. Jennifer also contributes as she handles essential functions in patient coordination. Located in Jacksonville, Florida, Shapiro Medical Group maintains an open-door policy ensuring continuous access to patient support before and after hair transplantation surgery. With a legacy of over 23 years, patient educator Matt works closely with clients to set realistic expectations through comprehensive consultations about microscopic follicular unit transplantations. Founded on January 19, 2018, the entity currently holds the Florida company status under filing number L18000017084 as an FLAL corporation. Operating from a mailing address in Jacksonville and maintaining a strong digital presence via shapiromedical.com, Shapiro Medical Group is committed to excellence and transparency for both current and prospective patients. The company's last reported annual activity occurred on January 21, 2024.